[Senile systemic amyloidosis: definition, diagnosis, why thinking about?]
Thibaud Damy1, Dania Mohty, Jean-Francois Deux
1CHU Henri-Mondor, fédération de cardiologie, 94000 Créteil, France. thibaud.damy@hmn.aphp.fr
Presse Medicale (Paris, France : 1983)
|May 15, 2013
Summary
Senile systemic amyloidosis (SSA) involves amyloid transthyretin buildup in the heart, primarily affecting elderly men. Early diagnosis is crucial to distinguish it from other cardiac amyloidosis types and manage potential complications like cardiomyopathy and stroke.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Amyloidosis Research
Context:
- Senile systemic amyloidosis (SSA) is a cardiac condition caused by amyloid transthyretin fibril deposition in the myocardium.
- SSA predominantly affects elderly individuals, often men, leading to significant cardiac dysfunction.
- The condition can manifest as hypertrophic or restrictive cardiomyopathy, with risks of conduction disturbances, atrial arrhythmias, and systemic embolization.
Purpose:
- To highlight the diagnostic challenges and importance of identifying cardiac amyloidosis, specifically SSA.
- To differentiate cardiac SSA from other forms, namely AL amyloidosis and hereditary transthyretin amyloidosis.
- To emphasize the role of scintigraphy, particularly 99mTc-DPD, in diagnosing cardiac amyloidosis.
Summary:
- Senile systemic amyloidosis (SSA) is characterized by the infiltration of amyloid transthyretin fibrils in the heart muscle.
- Diagnosis requires excluding AL amyloidosis and hereditary transthyretin amyloidosis, often utilizing 99mTc-DPD scintigraphy.
- DPD heart retention is a key indicator, being more prevalent in cardiac transthyretin amyloidosis than AL amyloidosis.
Impact:
- Early and accurate diagnosis of SSA is essential for appropriate patient management and care.
- Distinguishing SSA from other cardiac amyloidosis forms is critical for guiding treatment strategies.
- The development of specific treatments for cardiac transthyretin amyloidosis offers future therapeutic hope.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...